SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BIAF

bioAffinity Technologies, Inc. (NASDAQ:BIAF)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$1.74-$0.11 (-5.91%)
 
Market cap
$10.9M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 1, 2022
Market Cap$10.94M-91.6%
Revenue (ttm)$5.53M-18.5%
Net Income-$15.41M-4.6%
EPS-$2.45+82.2%
Shares Out6.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,871.887
Open$1.80
Previous Close$1.85
Day's Range$1.69 - $1.84
52-Week Range$1.69 - $80.70
Betan/a
AnalystsHold
Price Targetn/a
Earnings DateApr 5, 2027
-5.95% (1D)
No price history available.

About BIAF

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Address
3300 Nacogdoches Road, San Antonio, TX, 78217, US
Market Cap
11 million
Employees
57
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceBalanced
Sold
$1.18M
Bought
$1.04M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From BIAF’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.91%
5 Days
-25.62%
1 Month
-52.44%
6 Months
-93.01%
1 Year
-91.59%

$BIAF stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BIAF holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BIAF's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BIAF Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BIAF patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BIAF from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BIAF

VXFVanguard Extended Market ETF$10.77K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BIAF’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
71% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
29% of score
58

News check: Record test volume and commercialization momentum offset by Q3 earnings miss and declining sales, creating mixed near-term signals.

Recent Insider Activity

Buys
11
Sells
11
Buy Value
$1.04M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.